Literature DB >> 30292851

Minimally Invasive Approaches Do Not Compromise Outcomes for Pneumonectomy: A Comparison Using the National Cancer Database.

Mark W Hennon1, Abbinav Kumar2, Harshita Devisetty2, Thomas D'Amico3, Todd L Demmy1, Adrienne Groman4, Sai Yendamuri5.   

Abstract

INTRODUCTION: Minimally invasive approaches are increasingly being used for the conduct of complex surgical procedures. Whether the benefits of minimally invasive approaches compared to thoracotomy for sublobar and lobar lung resection for NSCLC are realized for patients undergoing pneumonectomy is not clear.
METHODS: The National Cancer Database was queried for patients who underwent pneumonectomy for NSCLC from 2010 to 2014. Case data from patients who underwent resection by minimally invasive surgery (MIS) were compared with those from patients who received thoracotomy (open) in an intention-to-treat analysis. Associations between potential covariates and treatment were analyzed using the Pearson chi-square test for categorical variables and Wilcoxon rank sum test for continuous variables. Univariable and multivariable logistic models and proportional hazards model were used to assess the effect of surgical approach on 30-day and 90-day mortality and overall survival. Relative prognosis was summarized using odds ratios and hazards ratios estimates and 95% confidence limits.
RESULTS: A total of 4,938 patients underwent pneumonectomy during the study period, of which 755 (15.3%) were completed by MIS. No difference was noted in 30- and 90-day mortality rates for MIS compared to open approaches (6.8% and 12.3% versus 6.7% and 11.9%, respectively; p = 0.9 and 0.86, respectively). Tumor histology and stage characteristics were similar between the two groups. The mean number of lymph nodes examined was higher in the MIS group compared to the open thoracotomy group (17.1 ± 0.4 versus 16.1 ± 0.2, p = 0.034). The conversion rate for the MIS cohort was 36.7%. Surgical approach was not associated with any difference in perioperative mortality with univariable or multivariable analysis. MIS was associated with improved overall survival on univariable analysis, but this was not evident with multivariable analysis.
CONCLUSIONS: Pneumonectomy performed by minimally invasive approaches does not compromise perioperative mortality or long-term outcomes. Further investigation into the impact of minimally invasive approaches on perioperative outcomes for whole-lung resection is warranted.
Copyright © 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lung cancer; Minimally invasive; NSCLC; Pnumonectomy; VATS

Mesh:

Year:  2018        PMID: 30292851     DOI: 10.1016/j.jtho.2018.09.024

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  6 in total

Review 1.  Early-Stage NSCLC: Advances in Thoracic Oncology 2018.

Authors:  Raymond U Osarogiagbon; Giulia Veronesi; Wentao Fang; Simon Ekman; Kenichi Suda; Joachim G Aerts; Jessica Donington
Journal:  J Thorac Oncol       Date:  2019-03-07       Impact factor: 15.609

2.  Approach to Resectable N1 Non-Small Cell Lung Cancer: An Analysis of the National Cancer Database.

Authors:  Chan Y Pu; Sarah Rodwin; Bre Nelson; Najya Fayyaz; Nicholas Scott; Rene J Bouchard; Adrienne Groman; Mark Hennon; Sai Yendamuri
Journal:  J Surg Res       Date:  2020-12-03       Impact factor: 2.417

Review 3.  [Pneumonectomy for Non-small Cell Lung Cancer: Predictors of Operative Mortality and Survival].

Authors:  Xiaokang Guo; Huafeng Wang; Yucheng Wei
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-07-20

4.  A meta-analysis of minimally invasive surgery versus thoracotomy for centrally located non-small cell lung cancer.

Authors:  Zhengjun Li; Mozhu Xia; Chang Liu; Tao Wang; Yi Ren; Yongyu Liu
Journal:  J Thorac Dis       Date:  2021-01       Impact factor: 2.895

5.  Role of Pneumonectomy in T1-4N2M0 Non-Small Cell Lung Cancer: A Propensity Score Matching Analysis.

Authors:  Suyu Wang; Qing Wang; Wanli Zhu; Juan Wei; Di Feng; Xin Lv; Meiyun Liu
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

6.  Comparison of perioperative outcomes among non-small cell lung cancer patients with neoadjuvant immune checkpoint inhibitor plus chemotherapy, EGFR-TKI, and chemotherapy alone: a real-world evidence study.

Authors:  Deping Zhao; Long Xu; Junqi Wu; Yunlang She; Hang Su; Likun Hou; Haoran E; Lei Zhang; Francesco Grossi; Melanie P Subramanian; Anthony W Kim; Yuming Zhu; Chang Chen
Journal:  Transl Lung Cancer Res       Date:  2022-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.